Literature DB >> 16991199

High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS.

Eric Schiffer1, Harald Mischak, Jan Novak.   

Abstract

All organisms contain thousands of proteins and peptides in their body fluids. A deeper insight into the functional relevance of these polypeptides under different physiological and pathophysiological conditions and the discovery of specific peptide biomarkers would greatly enhance both diagnosis and therapy of specific diseases. Proteomic methods can provide means to accomplish this grand medical vision. In this review, we will focus on the potential use of proteome analysis for clinical applications, such as disease diagnosis and assessment of response to therapy. We focus on CE coupled with MS (CE-MS) and review in detail different aspects of CE-MS coupling and the results obtained using CE-MS analysis of clinically relevant samples. We also discuss clinical applications of the technology for the diagnosis of renal diseases, urogenital cancer, and arteriosclerosis as well as monitoring the responses to therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16991199     DOI: 10.1002/pmic.200600230

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  23 in total

Review 1.  Mass spectrometry based proteomics in urine biomarker discovery.

Authors:  Dan Theodorescu; Harald Mischak
Journal:  World J Urol       Date:  2007-08-17       Impact factor: 4.226

2.  High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine.

Authors:  Harald Mischak; Bruce A Julian; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2007-07-10       Impact factor: 3.494

Review 3.  Urinary biomarkers for renal tract malformations.

Authors:  Pedro Magalhães; Joost P Schanstra; Emma Carrick; Harald Mischak; Petra Zürbig
Journal:  Expert Rev Proteomics       Date:  2016-11-15       Impact factor: 3.940

Review 4.  Proteomic urinary biomarker approach in renal disease: from discovery to implementation.

Authors:  Joost P Schanstra; Harald Mischak
Journal:  Pediatr Nephrol       Date:  2014-03-15       Impact factor: 3.714

Review 5.  -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Int J Biol Markers       Date:  2011-09-21       Impact factor: 2.659

6.  The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease.

Authors:  Petra Zürbig; Stéphane Decramer; Mohammed Dakna; Justyna Jantos; David M Good; Joshua J Coon; Flavio Bandin; Harald Mischak; Jean-Loup Bascands; Joost P Schanstra
Journal:  Proteomics       Date:  2009-04       Impact factor: 3.984

Review 7.  Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease.

Authors:  Cécile Caubet; Chrystelle Lacroix; Stéphane Decramer; Jens Drube; Jochen H H Ehrich; Harald Mischak; Jean-Loup Bascands; Joost P Schanstra
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

8.  Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles.

Authors:  Masahiro Sugimoto; David T Wong; Akiyoshi Hirayama; Tomoyoshi Soga; Masaru Tomita
Journal:  Metabolomics       Date:  2009-09-10       Impact factor: 4.290

Review 9.  Proteomics and opportunities for clinical translation in urological disease.

Authors:  Ali R Vaezzadeh; Hanno Steen; Michael R Freeman; Richard S Lee
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

Review 10.  Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.

Authors:  Jochen Metzger; Peter B Luppa; David M Good; Harald Mischak
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.